Assessment of a causal relationship between body mass index and atopic dermatitis - 09/01/21
Doi : 10.1016/j.jaci.2020.04.050
Ashley Budu-Aggrey, PhD a, b, ∗, Sarah H. Watkins, PhD a, b, ∗, Ben Brumpton, PhD a, c, d, ∗, Mari Løset, MD, PhD c, e, Jess Tyrrell, PhD f, Ellen H. Modalsli, MD, PhD e, g, h, Gunnhild Åberge Vie, PhD h, Tom Palmer, PhD a, b, Lars G. Fritsche, PhD c, Jonas Bille Nielsen, MD, PhD c, i, Pål Richard Romundstad, PhD h, George Davey Smith, MD, DSc a, b, Bjørn Olav Åsvold, MD, PhD c, j, ‡, Lavinia Paternoster, PhD a, b, ‡, Sara J. Brown, FRCPE k, l, ‡ 
a Medical Research Council Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
b Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
c K.G. Jebsen Center for Genetic Epidemiology, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
d Department of Thoracic and Occupational Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
e Department of Dermatology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
f Genetics of Complex Traits, Institute of Biomedical and Clinical Science, University of Exeter Medical School, Royal Devon and Exeter Hospital, Exeter, United Kingdom
g Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
h Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Trondheim, Norway
i Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Mich
j Department of Endocrinology, St Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
k Skin Research Group, School of Medicine, University of Dundee, Dundee, United Kingdom
l Department of Dermatology, Ninewells Hospital and Medical School, Dundee, United Kingdom
| A.B-A. is funded by a grant awarded to L.P. by the British Skin Foundation (8010 Innovative Project). A.B-A, L.P., S.W., and G.D.S. work in a research unit funded by the UK Medical Research Council (MC_UU_00011/1). B.B., M.L., L.G.F., and B.O.A. work in a research unit funded by Stiftelsen Kristian Gerhard Jebsen, Faculty of Medicine and Health Sciences, NTNU; The Liaison Committee for Education, Research, and Innovation in Central Norway; and the Joint Research Committee between St. Olav's Hospital and the Faculty of Medicine and Health Sciences, NTNU. J.T. is supported by an Academy of Medical Sciences Springboard award, which is supported by the Academy of Medical Sciences, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation, and Diabetes UK. E.H.M. was supported by a research grant from the Liaison Committee for Education, Research and Innovation in Central Norway. G.A.V. is supported by a research grant from the Norwegian Research Council (grant 250335). M.L. is supported by research grants from the Liaison Committee for Education, Research and Innovation in Central Norway. J.B.N. was supported by grants from the Danish Heart Foundation and the Lundbeck Foundation. L.P. is supported by an Academy of Medical Sciences Springboard Award, which is supported by the Wellcome Trust, the Government Department for Business, Energy and Industrial Strategy, the Global Challenges Research Fund, and the British Heart Foundation [SBF003/1094]. S.J.B. holds a Wellcome Trust Senior Research Fellowship in Clinical Science (106865/Z/15/Z) and a British Skin Foundation large project grant. The genotyping in HUNT was financed by the National Institutes of Health; the University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research, and Innovation in Central Norway; and the Joint Research Committee between St. Olav's Hospital and the Faculty of Medicine and Health Sciences, NTNU. The funders had no influence on study design, data collection and analysis, decision to publish, or preparation of the article. |
|
| Disclosure of potential conflict of interest: L. Paternoster has received personal fees from Merck for Scientific Input Engagement related to MR methodology. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 147 - N° 1
P. 400-403 - Gennaio 2021 Ritorno al numero
Articolo precedente
- Low-dose capsaicin (0.01 mM) nasal spray is equally effective as the current standard treatment for idiopathic rhinitis: A randomized, double-blind, placebo-controlled trial
- Laura Van Gerven, Brecht Steelant, Leen Cools, Ina Callebaut, Wout Backaert, Jan de Hoon, Els Ampe, Karel Talavera, Peter W. Hellings
- Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A?32:01–positive vancomycin-induced DRESS sharing an HLA class II haplotype
- Nontaya Nakkam, Andrew Gibson, Effie Mouhtouris, Katherine C. Konvinse, Natasha E. Holmes, Kyra Y. Chua, Pooja Deshpande, Danmeng Li, David A. Ostrov, Jason Trubiano, Elizabeth J. Phillips
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?